José Luis Zamorano
University of Alcalá
Internal medicineRadiologySurgeryHumanitiesCardiologyIntensive care medicineHeart failureCoronary artery diseaseVentricleDiseaseAtrial fibrillationMEDLINEStenosisPopulationTask forceIn patientMyocardial infarctionStrokeMedicineEjection fraction
494Publications
112H-index
54.8kCitations
Publications 750
Newest
#1Fabien Praz (University of Bern)H-Index: 29
#2Denisa MuraruH-Index: 38
Last. Jörg HausleiterH-Index: 71
view all 14 authors...
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve apparatus and is observed in only 8-10% of the patients with tricuspid valve disease. Secondary TR is more common and arises as a result of annular dilation caused by right ventricular enlargement and dysfunction as a consequence of pulmonary hypertension, often caused by left-sided heart disease or atrial fibrillation. Ir...
Source
Source
Introduction and objectives: Most multi-biomarker strategies in acute heart failure (HF) have only measured biomarkers in a single-point time. This study aimed to evaluate the prognostic yielding of NT-proBNP, hsTnT, Cys-C, hs-CRP, GDF15, and GAL-3 in HF patients both at admission and discharge. Methods: We included 830 patients enrolled consecutively in a prospective multicenter registry. Primary outcome was 12-month mortality. The gain in the C-index, calibration, net reclassification improvem...
Source
Source
Source
Abstract null null Background null Right ventricle (RV) dilatation and dysfunction are established criteria for intervention in severe tricuspid regurgitation (TR); however thresholds to support intervention are lacking. New measures of RV function such as RV shortening (RVS) and effective RV ejection fraction (eRVEF) may be earlier markers of RV dysfunction. null null null Purpose null to compare the prognostic impact of different parameters of RV function and to describe cut-off values of RV s...
Source
#1Frank L.J. VisserenH-Index: 66
#2François MachH-Index: 83
Last. Davide CapodannoH-Index: 76
view all 106 authors...
Source
Abstract Background The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been...
Source
Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions but to date only one official position paper related to left circulation thromboembolism has been published. This interdisciplinary paper, prepared with the involvement of eight European scientific societies, reviews the available evidence and proposes a rationale for decision making for other PFO-related clinical conditions. In order to guarantee a strict evidence-based process, we used a modified gra...
Source
#1Gregory G. Schwartz (University of Colorado Denver)H-Index: 54
#2Michael Szarek (University of Colorado Denver)H-Index: 33
Last. Robert Pordy (Regeneron)H-Index: 27
view all 1672 authors...
Abstract null null Background null Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. null null null Objectives null In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovasc...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.